HomeCompareCBLNY vs MRK

CBLNY vs MRK: Dividend Comparison 2026

CBLNY yields 4.23% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBLNY wins by $2442.35M in total portfolio value
10 years
CBLNY
CBLNY
● Live price
4.23%
Share price
$5.10
Annual div
$0.22
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2442.41M
Annual income
$2,336,327,465.61
Full CBLNY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CBLNY vs MRK

📍 CBLNY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBLNYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBLNY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBLNY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBLNY
Annual income on $10K today (after 15% tax)
$359.62/yr
After 10yr DRIP, annual income (after tax)
$1,985,878,345.77/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CBLNY beats the other by $1,985,870,017.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBLNY + MRK for your $10,000?

CBLNY: 50%MRK: 50%
100% MRK50/50100% CBLNY
Portfolio after 10yr
$1221.23M
Annual income
$1,168,168,631.87/yr
Blended yield
95.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CBLNY
No analyst data
Altman Z
2.6
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBLNY buys
0
MRK buys
0
No recent congressional trades found for CBLNY or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBLNYMRK
Forward yield4.23%2.76%
Annual dividend / share$0.22$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$2442.41M$56.8K
Annual income after 10y$2,336,327,465.61$9,798.13
Total dividends collected$2434.86M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CBLNY vs MRK ($10,000, DRIP)

YearCBLNY PortfolioCBLNY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,546$846.16$11,206$366.19+$340.00CBLNY
2$14,181$1,826.14$12,650$502.35+$1.5KCBLNY
3$19,365$4,192.14$14,407$694.19+$5.0KCBLNY
4$31,422$10,700.74$16,585$967.82+$14.8KCBLNY
5$66,075$32,453.71$19,342$1,363.89+$46.7KCBLNY
6$198,261$127,561.06$22,913$1,947.19+$175.3KCBLNY
7$927,567$715,427.77$27,662$2,823.89+$899.9KCBLNY
8$7,248,829$6,256,331.97$34,159$4,173.35+$7.21MCBLNY
9$99,144,099$91,387,852.40$43,337$6,308.80+$99.10MCBLNY
10$2,442,411,652$2,336,327,465.61$56,776$9,798.13+$2442.35MCBLNY

CBLNY vs MRK: Complete Analysis 2026

CBLNYStock

Mersen SA manufactures and sells electrical power products and advanced materials in France, North America, rest of Europe, the Asia-Pacific, and internationally. It operates through Advanced Materials and Electrical Power segments. The company offers electrical protection and control products, such as IEC and UL/CSA low voltage general purpose fuses and fuse gears, high and medium voltage fuses, and power transfer solutions for rail vehicles, as well as surge protection, lightning protection, and power monitoring solutions; and power management solutions, including high speed fuses, DC protection for electric vehicles and battery, cooling solutions, bus bars, and aluminum electrolytic and film capacitors. It also provides anticorrosion equipment comprising heat exchangers; columns, reactors, and pressure vessels; PTFE or PFA bellows, pipes, elbows, and fittings; graphite bursting discs; corrosion resistant materials; and after-sales and maintenance services, as well as graphite specialties, such as isostatic graphite, carbon insulation, extruded graphite, carbon/carbon composites, silicon carbide, and flexible graphite. In addition, the company offers carbon brushes, brush-holders, brush-rockers and brush gear housings, signal and power transmission systems, rotary joints, current collectors, wheel flange lubrication solutions, carbon dust collection systems, and monitoring solutions, as well as slip, pitch control, and electrical ring assemblies. It serves energy, electronics, transportation, corrosive chemicals, and process industries, as well as other markets comprising building, elevator, ski lifts, defense, HVAC, and outdoor LED lighting markets. The company was formerly known as Groupe Carbone Lorraine SA and changed its name to Mersen SA in 2010. Mersen SA was founded in 1889 and is headquartered in Courbevoie, France.

Full CBLNY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CBLNY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBLNY vs SCHDCBLNY vs JEPICBLNY vs OCBLNY vs KOCBLNY vs MAINCBLNY vs JNJCBLNY vs ABBVCBLNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.